Exencial Wealth Advisors LLC Sells 3,070 Shares of GSK plc (NYSE:GSK)

Exencial Wealth Advisors LLC cut its position in shares of GSK plc (NYSE:GSK) by 6.3% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 45,868 shares of the pharmaceutical company’s stock after selling 3,070 shares during the quarter. Exencial Wealth Advisors LLC’s holdings in GSK were worth $1,551,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in GSK. FMR LLC boosted its holdings in GSK by 8.3% in the third quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock worth $1,185,885,000 after acquiring an additional 2,224,345 shares in the last quarter. Fisher Asset Management LLC boosted its holdings in GSK by 4.9% in the third quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock worth $759,425,000 after acquiring an additional 870,449 shares in the last quarter. Clifford Capital Partners LLC boosted its holdings in GSK by 14.3% in the third quarter. Clifford Capital Partners LLC now owns 409,669 shares of the pharmaceutical company’s stock worth $16,747,000 after acquiring an additional 51,378 shares in the last quarter. Cerity Partners LLC boosted its holdings in GSK by 61.8% in the third quarter. Cerity Partners LLC now owns 433,628 shares of the pharmaceutical company’s stock worth $17,728,000 after acquiring an additional 165,556 shares in the last quarter. Finally, Natixis Advisors LLC boosted its holdings in GSK by 20.0% in the third quarter. Natixis Advisors LLC now owns 500,495 shares of the pharmaceutical company’s stock worth $20,460,000 after acquiring an additional 83,433 shares in the last quarter. 15.74% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the company. StockNews.com raised GSK from a “buy” rating to a “strong-buy” rating in a report on Friday, February 7th. Morgan Stanley assumed coverage on GSK in a report on Wednesday, February 12th. They issued an “equal weight” rating on the stock. Jefferies Financial Group cut GSK from a “buy” rating to a “hold” rating and decreased their price target for the stock from $53.00 to $39.50 in a research note on Tuesday, November 12th. Finally, Deutsche Bank Aktiengesellschaft cut GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Seven equities research analysts have rated the stock with a hold rating and four have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Stock Up 0.9 %

GSK stock opened at $38.79 on Thursday. GSK plc has a 1-year low of $31.72 and a 1-year high of $45.92. The business has a fifty day moving average price of $35.25 and a 200-day moving average price of $37.20. The company has a debt-to-equity ratio of 1.12, a current ratio of 0.78 and a quick ratio of 0.52. The stock has a market capitalization of $80.38 billion, a P/E ratio of 24.39, a P/E/G ratio of 1.12 and a beta of 0.58.

GSK (NYSE:GSK) last posted its quarterly earnings data on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, beating analysts’ consensus estimates of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. Equities analysts forecast that GSK plc will post 4.14 earnings per share for the current fiscal year.

GSK Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, April 10th. Investors of record on Friday, February 21st will be given a dividend of $0.3932 per share. This represents a $1.57 dividend on an annualized basis and a yield of 4.05%. The ex-dividend date of this dividend is Friday, February 21st. This is a boost from GSK’s previous quarterly dividend of $0.39. GSK’s dividend payout ratio is 98.74%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.